Class Action Certification Announcement
A significant class action lawsuit involving Johnson & Johnson and their drug Stelara has garnered attention recently. The court has officially certified a class of third-party payors who either purchased or paid for all or part of the drug's price. This announcement marks a critical moment for these payors, as their rights may be significantly impacted by the ongoing legal proceedings.
Overview of the Lawsuit
The case, known as CareFirst of Maryland v. Johnson & Johnson, is currently pending in the Eastern District of Virginia. Allegations within this lawsuit cite that the defendants engaged in practices that violate antitrust and consumer protection laws. The core accusation is that J&J knowingly maintained monopoly power while harming competition in the market for ustekinumab, which is the active ingredient in Stelara.
According to the lawsuit, the defendants fraudulently acquired patents related to the drug, allowing them to unlawfully delay the entry of biosimilars into the market. This delay resulted in third-party payors being forced to pay inflated prices for Stelara, which ultimately affected consumer costs as well.
Who is Affected by the Class Action?
Any third-party payor that paid for Stelara as part of a prescription drug benefit could be included in the class. Specifically, those who purchased or paid for this medication from January 1, 2024, to December 31, 2025, fall within the criteria for the class period. However, certain entities are excluded from participation, including J&J, governmental entities, and those whose purchases were made exclusively through Medicaid plans.
Membership and Exclusions
Membership in the class is determined based on specific criteria laid out by the court. If you find yourself part of this group, it is crucial to understand your options. Conversely, if you wish to retain the right to file a lawsuit individually against J&J, you must formally exclude yourself from the class.
Legal Representation and Participation
The court has appointed a group of attorneys to represent the class, ensuring that participants do not incur costs to join the lawsuit. When funds or benefits are obtained for the class, the lawyers may apply for fees, which would be deducted from any overall recovery.
As a member of the class, you have the option to do nothing and potentially benefit from any settlement or judgment that results from the trial. However, by remaining inactive, you will be bound by court orders and will be unable to pursue independent claims against J&J regarding these issues.
The Court Proceedings Ahead
A trial is scheduled for January 26, 2026, located at the United States Courthouse in Norfolk, Virginia. Updates regarding any changes in dates or locations will be made available on the case's official website, allowing interested parties to keep informed.
How to Get More Information
If you seek further details, you can visit the designated case website or reach out via phone. For inquiries specific to exclusions, a separate mailing address has been established for that purpose. All participants are encouraged to stay informed and engaged as the trial date approaches.
Frequently Asked Questions
What is Stelara?
Stelara is a medication used to treat certain autoimmune conditions. Its price has been a contentious issue leading to the current class action suit.
Who can join the class action?
Members include third-party payors who purchased or paid for Stelara from January 1, 2024, to December 31, 2025, but not those affiliated with J&J or federal and state entities.
What are the implications of the lawsuit?
This lawsuit could potentially impact the pricing and accessibility of Stelara, as well as shape market competition for similar medications.
How can I exclude myself from the class?
To keep your right to sue individually, you must follow the specific exclusion instructions provided in the Long-Form Notice.
Where can I find more information about the case?
Additional details about the lawsuit can be found on the case website or by calling the provided helpline for updates.
